- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT04471844
Klíčová, randomizovaná, otevřená studie Optune® (pole pro léčbu nádorů) současně s RT a TMZ pro léčbu nově diagnostikované GBM (EF-32)
EF-32: Pivotální, randomizovaná, otevřená studie Optune® (Tumor Treating Fields, 200 kHz) současně s radiační terapií a temozolomidem pro léčbu nově diagnostikovaného glioblastomu
To test the effectiveness and safety of Optune® given concomitantly with radiation therapy (RT) and temozolomide (TMZ) in newly diagnosed GBM patients, compared to radiation therapy and temozolomide alone. In both arms, Optune® and maintenance temozolomide are continued following radiation therapy.
Přehled studie
Detailní popis
Optune® is a medical device that has been approved for the treatment of recurrent and newly diagnosed glioblastoma (GBM) by the Food and Drug Administration (FDA) in the United States. Optune® has obtained a CE mark in Europe for recurrent and newly diagnosed GBM.
The current standard of care for GBM includes the addition of Optune® to maintenance temozolomide (TMZ), following the completion of radiation therapy (RT).
The purpose of the current study is to test if the earlier introduction of Optune®, at the time of radiation therapy (which is given together with temozolomide), improves clinical outcomes compared to the standard of care.
The study will randomize 950 subjects equally to one of two treatment arms:
- Treatment arm I: Patients receive TTFields at 200 kHz to the brain using the Optune® System together with RT and TMZ, followed by maintenance TMZ concomitant with the Optune® treatment.
- Treatment arm II: Patients receive RT and TMZ alone, followed by maintenance TMZ concomitant with TTFields at 200 kHz to the brain using the Optune®.
All patients are to receive standard RT and TMZ treatment followed by maintenance TMZ chemotherapy and Optune® according to the current standard of care regimen.
Optune® will continue until second disease progression per 2010 RANO Criteria unless any of the treatment discontinuation conditions described under criteria for patient withdrawal or termination are met.
After surgery or biopsy, subjects that would like to participate will be required to submit samples of their tumor to a lab for testing. The results of this test will be used for randomization into the trial.
If the subject is assigned to the treatment group that will start Optune® therapy during radiation therapy, Optune® therapy will begin within 10 days of enrolling in the study and no later than the first day of RT and TMZ treatment.
After the initial visit, subjects will continue treatment at home, while pursuing normal daily routines. Subjects are required to use the device for at least 18 hours a day. Short breaks in treatment for personal hygiene and other personal needs is allowed. Total usage time will be recorded and provided to the site and sponsor.
Subjects will be required to return to the clinic per the study protocol.
After the second disease progression, subjects will return to the clinic for one final visit approximately 30 days after the last treatment with Optune® or after second disease progression, the latter of the two per protocol.
After completing active participation in the study, subjects will be contacted once per month to answer basic questions about their health status.
Typ studie
Zápis (Aktuální)
Fáze
- Nelze použít
Kontakty a umístění
Studijní místa
-
-
-
Liège, Belgie, B35, 4000
- University Hospital Liege - Sart Tilman
-
-
-
-
-
Angers, Francie, 49055
- Institut de cancérologie de l'Ouest
-
Bron, Francie, 69677
- Pierre Wertheimer Hospital
-
Marseille, Francie, 13305
- Hôpital la Timone
-
Nice, Francie, 06000
- University Hospital Nice
-
Paris, Francie, 75013
- Pitié-Salpêtrière University Hospital
-
Saint-Herblain, Francie, 44800
- Institut de cancérologie de l'Ouest
-
Toulouse, Francie, 31059
- University Institute Cancer Toulouse Oncopole
-
Villejuif, Francie, 94805
- Gustave Roussy Institute
-
-
-
-
-
Jerusalem, Izrael, 9112001
- Hadassah Medical Center - Ein Kerem
-
-
Haifa District
-
Haifa, Haifa District, Izrael, 3109601
- Rambam Medical Center
-
-
Petah Tikva
-
Petah Tikva, Petah Tikva, Izrael, 49100
- Rabin Medical Center
-
-
Ramat Gan
-
Ramat Gan, Ramat Gan, Izrael, 52621
- Sheba Medical Center
-
-
Tel Aviv
-
Tel Aviv, Tel Aviv, Izrael, 64239
- Tel Aviv Sourasky Medical Center
-
-
-
-
Hokkaido
-
Sapporo, Hokkaido, Japonsko, 060-8648
- Hokkaido University Hospital
-
-
Ishikawa-ken
-
Kanazawa, Ishikawa-ken, Japonsko, 920-8641
- Kanazawa University Hospital
-
-
Saitama
-
Hidaka-shi, Saitama, Japonsko, 350-1298
- Saitama Medical University International Medical Center
-
-
Tokyo-To
-
Mitaka-shi, Tokyo-To, Japonsko, 181-8611
- Kyorin University Hospital
-
Shinjuku-ku, Tokyo-To, Japonsko, 162-8666
- Tokyo Women's Medical University Hospital
-
-
-
-
British Columbia
-
Vancouver, British Columbia, Kanada, V5Z 4E6
- BC Cancer - Vancouver
-
-
Nova Scotia
-
Sydney, Nova Scotia, Kanada, B1P 1P3
- Nova Scotia Health Authority
-
-
Ontario
-
Ottawa, Ontario, Kanada
- The Ottawa Hospital Cancer Centre
-
Toronto, Ontario, Kanada
- Princess Margaret Cancer Centre
-
Toronto, Ontario, Kanada
- Sunnybrook Research Institute - Odette Cancer Centre
-
-
Quebec
-
Montreal, Quebec, Kanada, H2X1R9
- CHUM Centre de Recherche
-
Sherbrooke, Quebec, Kanada
- Universite de Sherbrooke - Sherbrooke Centre Hospitalier Universita
-
-
-
-
-
Essen, Německo, 45147
- University Hospital Essen
-
Freiburg im Breisgau, Německo, 79106
- University Medical Center Freiburg
-
Leipzig, Německo, 04103
- University Hospital Leipzig
-
Munich, Německo, 81675
- Rechts der Isar Hospital
-
Tübingen, Německo, 72076
- University Hospital Tübingen
-
-
-
-
Innsbruck
-
Innsbruck, Innsbruck, Rakousko, 6020
- Innsbruck University Hospital
-
-
Linz
-
Linz, Linz, Rakousko, 4020
- Kepler University Hospital
-
-
State of Salzburg
-
Salzburg, State of Salzburg, Rakousko, 5020
- University Hospital Salzburg
-
-
-
-
-
Liverpool, Spojené království, L7 8YA
- Clatterbridge Cancer Centre
-
London, Spojené království, SE1 9RT
- Guy's Hospital
-
London, Spojené království, W6 8RF
- Charing Cross Hospital
-
Nottingham, Spojené království, NG5 1PB
- Nottingham University Hospitals NHS Trust
-
Preston, Spojené království, PR29HT
- Royal Preston Hospital
-
-
-
-
Alabama
-
Birmingham, Alabama, Spojené státy, 35243
- Grandview Cancer Center
-
-
Arizona
-
Gilbert, Arizona, Spojené státy, 85234
- Banner MD Anderson Cancer Center
-
Phoenix, Arizona, Spojené státy, 85054
- Mayo Clinic- Arizona
-
Tucson, Arizona, Spojené státy, 85719
- University of Arizona Cancer Center
-
-
Arkansas
-
Fayetteville, Arkansas, Spojené státy, 72762
- Highlands Oncology Group
-
-
California
-
Burbank, California, Spojené státy, 91505
- Providence St. Joseph Medical Center and The Roy and Patricia Disney Family Cancer Center
-
Duarte, California, Spojené státy, 91010
- City of Hope National Medical Center
-
Fullerton, California, Spojené státy, 92835
- TRIO - St. Jude Heritage Healthcare/St. Jude Medical Center
-
La Jolla, California, Spojené státy, 92093
- University of California at San Diego - Moores Cancer Center
-
Los Angeles, California, Spojené státy, 90048
- Cedars - Sinai Medical Center
-
Los Angeles, California, Spojené státy, 90033
- Norris Comprehensive Cancer Center at USC
-
Newport Beach, California, Spojené státy, 92663
- Hoag Memorial Hospital - Hoag Cancer Center
-
Orange, California, Spojené státy, 92868
- St. Joseph Hospital of Orange
-
Orange, California, Spojené státy, 92868
- University of California - Irvine/UCI Medical Center
-
Palo Alto, California, Spojené státy, 94303
- Stanford University Cancer Institute
-
San Diego, California, Spojené státy, 92123
- Sharp Memorial Hospital - X-Ray Medical Group Radiation Oncology
-
San Francisco, California, Spojené státy, 94143
- University of California San Francisco Medical Center
-
Santa Monica, California, Spojené státy, 90404
- John Wayne Cancer Institute at St. John's Health Center
-
-
Colorado
-
Aurora, Colorado, Spojené státy, 80045
- University of Colorado Cancer Center Anschutz
-
Englewood, Colorado, Spojené státy, 80113
- HCA Research Institute - Blue Sky Neurology - Denver
-
-
Connecticut
-
Hartford, Connecticut, Spojené státy, 06106
- Hartford Healthcare Medical Group - Hartford Hospital The Gray Cancer Center
-
-
Florida
-
Boca Raton, Florida, Spojené státy, 33486
- Lynn Cancer Institute, Marcus Neuroscience Institute
-
Jacksonville, Florida, Spojené státy, 32224
- Mayo Clinic
-
Jacksonville, Florida, Spojené státy, 32207
- Baptist Health - Jacksonville
-
Orlando, Florida, Spojené státy, 32804
- AdventHealth
-
Orlando, Florida, Spojené státy, 32806
- Orlando Health UF Health Cancer Center
-
Tampa, Florida, Spojené státy, 33612
- H. Lee Moffitt Cancer Center and Research Institute, Inc
-
-
Georgia
-
Atlanta, Georgia, Spojené státy, 30342
- Northside Hospital, Inc.
-
Atlanta, Georgia, Spojené státy, 30309
- Piedmont Healthcare Brain Tumor Center
-
Atlanta, Georgia, Spojené státy, 30322
- The Emory Clinic - Emory Healthcare - Winship Cancer Institute
-
-
Illinois
-
Chicago, Illinois, Spojené státy, 60612
- Rush University Medical Center
-
Chicago, Illinois, Spojené státy, 60617
- University of Chicago
-
-
Indiana
-
Fort Wayne, Indiana, Spojené státy, 46845
- Parkview Cancer Institute - Fort Wayne Radiation Oncology Associates
-
-
Kansas
-
Topeka, Kansas, Spojené státy, 66606
- The University of Kansas Cancer Center
-
-
Kentucky
-
Louisville, Kentucky, Spojené státy, 40241
- Norton Cancer Institute
-
Louisville, Kentucky, Spojené státy, 40202
- University of Louisville - James Graham Brown Cancer Center
-
-
Louisiana
-
Baton Rouge, Louisiana, Spojené státy, 70810
- Mary Bird Cancer Center Neuromedical Center
-
New Orleans, Louisiana, Spojené státy, 70072
- LSU Health Sciences Center, New Orleans
-
New Orleans, Louisiana, Spojené státy, 70121-2429
- Ochsner Health System
-
-
Maine
-
South Portland, Maine, Spojené státy, 04106
- Maine Medical Partners Neurology - Neurosurgery & Spine Associates
-
-
Maryland
-
Baltimore, Maryland, Spojené státy, 21287
- John Hopkins School of Medicine
-
-
Massachusetts
-
Boston, Massachusetts, Spojené státy, 02111
- Tufts Medical Center
-
Worcester, Massachusetts, Spojené státy, 01655
- University of Massachusetts Chan Medical School
-
-
Michigan
-
Ann Arbor, Michigan, Spojené státy, 48109
- University of Michigan Comprehensive Cancer Center
-
-
Minnesota
-
Minneapolis, Minnesota, Spojené státy, 55407
- Abbott Northwestern Hospital - Givens Brain Tumor Center
-
-
Mississippi
-
Jackson, Mississippi, Spojené státy, 39216
- University of Mississippi Medical Center
-
-
Missouri
-
Columbia, Missouri, Spojené státy, 65212
- University of Missouri - Ellis Fischel Cancer Center
-
Kansas City, Missouri, Spojené státy, 64132
- Health Midwest Ventures Group, Inc - Sarah Cannon HCA Midwest Brain and Spine
-
St Louis, Missouri, Spojené státy, 63110
- Washington University School of Medicine
-
-
New Hampshire
-
Lebanon, New Hampshire, Spojené státy, 03756
- Dartmouth-Hitchcock Medical Center
-
-
New Jersey
-
Edison, New Jersey, Spojené státy, 08820
- JFK Neuroscience Institute, HMH JFK University Medical Center
-
Hackensack, New Jersey, Spojené státy, 07601
- Hackensack University Medical Center - John Theurer Cancer Center
-
Neptune City, New Jersey, Spojené státy, 07753
- Jersey Shore University Medical Center
-
-
New York
-
Lake Success, New York, Spojené státy, 11042
- Northwell Health System Brain Tumor Center
-
New York, New York, Spojené státy, 10029
- Mount Sinai - Icahn School of Medicine
-
New York, New York, Spojené státy, 10016
- NYU Langone - Laura & Issac Perimutter Cancer Center
-
New York, New York, Spojené státy, 10032
- New York Presbyterian - Columbia University
-
Rochester, New York, Spojené státy, 14642
- University of Rochester Medical Center
-
Syracuse, New York, Spojené státy, 13210
- SUNY Upstate Medical University
-
-
North Carolina
-
Chapel Hill, North Carolina, Spojené státy, 27599
- University of North Carolina Brain Tumor Program - UNC Lineberger Comprehensive Cancer Center
-
Charlotte, North Carolina, Spojené státy, 28204
- Novant Health Cancer Institute Radiation Oncology
-
Greenville, North Carolina, Spojené státy, 27834
- Vidant Medical Center
-
Winston-Salem, North Carolina, Spojené státy, 27157
- Wake Forest Baptist Comprehensive Cancer Center
-
Winston-Salem, North Carolina, Spojené státy, 27103
- Forsyth Medical Center-Novant Health
-
-
Ohio
-
Cincinnati, Ohio, Spojené státy, 45219
- University of Cincinnati Cancer Institute
-
Columbus, Ohio, Spojené státy, 43210
- The James Cancer Hospital and Solove Research Institute - Arthur G James Cancer Hospital
-
-
Oregon
-
Portland, Oregon, Spojené státy, 97239
- Oregon Health & Science University (OHSU)
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Spojené státy, 19107
- Thomas Jefferson University Hospital
-
Philadelphia, Pennsylvania, Spojené státy, 19104
- Neuroscience Center, Philadelphia - University of Pennsylvania
-
Pittsburgh, Pennsylvania, Spojené státy, 15232
- UPMC Hillman Cancer Center
-
Pittsburgh, Pennsylvania, Spojené státy, 15212
- Allegheny Health Network Cancer Institute
-
-
Rhode Island
-
Providence, Rhode Island, Spojené státy, 02903
- Rhode Island Hospital
-
-
South Carolina
-
Charleston, South Carolina, Spojené státy, 29425
- MUSC Radiation Oncology Brain & Spine Tumor Program
-
-
Tennessee
-
Chattanooga, Tennessee, Spojené státy, 37404
- SCRI - Tennessee Oncology
-
Germantown, Tennessee, Spojené státy, 38138
- West Cancer Center - Germantown
-
Nashville, Tennessee, Spojené státy, 37203
- SCRI - Tennessee Oncology
-
-
Texas
-
Austin, Texas, Spojené státy, 78705
- Texas Oncology Midtown - Austin Brain Tumor Center
-
Dallas, Texas, Spojené státy, 75246
- Baylor Charles A. Sammons Cancer Center - Baylor University Medical Center
-
Fort Worth, Texas, Spojené státy, 76104
- John Peter Smith Health Network - JPS Cancer Center
-
Houston, Texas, Spojené státy, 77030
- Houston Methodist Hospital
-
Houston, Texas, Spojené státy, 77030
- UT Health Mischer Neuroscience - Memorial Herman - UT Neurosciences
-
Temple, Texas, Spojené státy, 76508
- Baylor Scott & White Medical Center
-
-
Vermont
-
Burlington, Vermont, Spojené státy, 05401
- The University of Vermont Medical Center - University of Vermont Cancer Center
-
-
Washington
-
Seattle, Washington, Spojené státy, 98122
- Swedish Health Services
-
Seattle, Washington, Spojené státy, 98109
- UW Medical Center - Alvord Brain Tumor Center
-
-
West Virginia
-
Morgantown, West Virginia, Spojené státy, 26506
- West Virginia University Cancer Institute
-
-
-
-
Brno
-
Brno, Brno, Česko, 656 53
- Masaryk Memorial Cancer Institute
-
-
Pilsen
-
Pilsen, Pilsen, Česko, 305 99
- University Hospital Plzeň
-
-
Prague
-
Prague, Prague, Česko, 150 30
- Na Homolce Hospital
-
-
-
-
-
Lausanne, Švýcarsko, CH-1011
- Lausanne University Hospital
-
Zurich, Švýcarsko, 8091
- University Hospital Zurich
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
*Age Limits - 18 years or older outside of the US, 22 years or older within the US.
Inclusion Criteria:
- Histologically confirmed diagnosis of GBM according to WHO 2016 classification criteria.
- Age ≥ 22 years in US and Age ≥ 18 years in Ex-US
- Recovered from maximal debulking surgery, if applicable (gross total resection, partial resection, and biopsy-only patients are all acceptable)
- Planned treatment with RT/TMZ followed by TTFields and maintenance TMZ (150-200 mg/m2 daily x 5 d, q28 days)
- Karnofsky performance status ≥ 70
- Life expectancy ≥ least 3 months
- Participants of childbearing age must use highly effective contraception. An effective method of birth control is defined as one that results in a failure rate of less than 1% per year when used consistently and correctly. The Investigator must approve the selected method, and may consult with a gynecologist as needed.
- All patients must understand and voluntarily sign an informed consent document prior to any study related assessments/procedures being conducted.
- Stable or decreasing dose of corticosteroids for the last 7 days prior to randomization, if applicable.
- Concomitant RT with TMZ treatment planned to start no later than 8 weeks from surgery
- Women of childbearing potential must have a negative β-HCG pregnancy test documented within 14 days prior to randomization
- Is able to have MRI with contrast of the brain
Exclusion Criteria:
-
Progressive disease (per investigator's assessment)
-
Infratentorial or leptomeningeal disease
-
Participation in another clinical treatment study during the pre-treatment and/or the treatment phase of the study
-
Pregnancy or breast-feeding.
-
Significant co-morbidities at baseline which would preclude maintenance RT or TMZ treatment, as determined by the investigator:
- Thrombocytopenia (platelet count < 100 x 103/μL)
- Neutropenia (absolute neutrophil count < 1.5 x 103/μL)
- CTC grade 4 non-hematological Toxicity (except for alopecia, nausea, vomiting)
- Significant liver function impairment - AST or ALT > 3 times the upper limit of normal
- Total bilirubin > 1.5 x upper limit of normal
- Significant renal impairment (serum creatinine > 1.7 mg/dL, or > 150 µmol/l)
- History of any psychiatric condition that might impair patient's ability to understand or comply with the requirements of the study or to provide consent
-
Implanted pacemaker, defibrillator, deep brain stimulator, other implanted electronic devices in the brain, or documented clinically significant arrhythmias.
-
Evidence of increased intracranial pressure (midline shift > 5mm, clinically significant papilledema, vomiting and nausea or reduced level of consciousness)
-
History of hypersensitivity reaction to TMZ or a history of hypersensitivity to DTIC.
-
Additional malignancies that are progressing or required active treatment in the last two years.
-
Admitted to an institution by administrative or court order.
-
Known allergies to medical adhesives or hydrogel
-
A skull defect (such as, missing bone with no replacement)
-
Prior radiation treatment to the brain for the treatment of GBM
-
Any serious surgical/post-operative condition that may put the participant at risk according to the investigator.
-
Standard TTFields exclusion criteria include
- Active implanted medical devices
- Bullet fragments
- Skull defects
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: Optune® + RT + TMZ for 6 weeks
Optune® + RT + TMZ for 6 weeks, followed by Optune® + TMZ until the tumor progresses. Optune treatment is maintained until second disease progression. |
Optune® is a commercial, portable, battery-operated device intended for continuous home use, which delivers TTFields at a frequency of 200kHz to the brain by means of insulated transducer arrays. The Optune® device produces electric forces intended to disrupt cancer cell division. In treatment arm I, the patient starts Optune® concurrently with RT/TMZ for 6 weeks, followed by Optune® + TMZ until second disease progression. In treatment arm II, the patient starts RT/TMZ for 6 weeks, followed by Optune® + TMZ until second disease progression. |
|
Aktivní komparátor: RT +TMZ for 6 weeks
RT +TMZ for 6 weeks followed by Optune® + TMZ until the tumor progresses. Optune treatment is maintained until second disease progression. |
Optune® is a commercial, portable, battery-operated device intended for continuous home use, which delivers TTFields at a frequency of 200kHz to the brain by means of insulated transducer arrays. The Optune® device produces electric forces intended to disrupt cancer cell division. In treatment arm I, the patient starts Optune® concurrently with RT/TMZ for 6 weeks, followed by Optune® + TMZ until second disease progression. In treatment arm II, the patient starts RT/TMZ for 6 weeks, followed by Optune® + TMZ until second disease progression. |
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Overall Survival (OS)
Časové okno: 5 years
|
Survival will be measured from the time of randomization until date patient is alive. |
5 years
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Progression Free Survival (PFS)
Časové okno: 5 years
|
PFS will be measured from the date of randomization to the date of progression based on the 2010 RANO Criteria. |
5 years
|
|
1- and 2-year survival rates
Časové okno: 5 years
|
The analyses will be performed based on estimated proportions of patients who are on study at 12 and 24 months in both arms of the study. |
5 years
|
|
Overall Radiological response (ORR)
Časové okno: 5 years
|
The analyses will be performed based on the 2010 RANO criteria, and comparison between the rates of response. |
5 years
|
|
Next progression-free survival (PFS2)
Časové okno: 5 years
|
PFS2 will be measured from the time of randomization to second tumor progression. |
5 years
|
|
Progression-free survival at 6 (PFS6) and 12 months (PFS12)
Časové okno: 5 years
|
The analyses will be estimated proportions of patients who are progression-free at 6 and 12 months in both arms of the study. |
5 years
|
|
Severity and frequency of adverse events
Časové okno: 5 years
|
The analyses will be performed based on the incidence, severity, frequency of adverse events, and their association with study treatments. |
5 years
|
|
Quality of Life EORTC Questionnaire
Časové okno: 5 years
|
The analyses will be assessed using the EORTC QLQ C-30 questionnaire with BN-20 (brain symptom) supplement. |
5 years
|
|
The NANO scale
Časové okno: 5 years
|
The Neurological assessment in Neuro-Oncology will be assessed using the NANO scale questionnaire and per the 2010 RANO criteria. |
5 years
|
Spolupracovníci a vyšetřovatelé
Sponzor
Publikace a užitečné odkazy
Obecné publikace
- Miller R, Niazi M, Russial O, Poiset S, Shi W. Tumor treating fields with radiation for glioblastoma: a narrative review. Chin Clin Oncol. 2022 Oct;11(5):40. doi: 10.21037/cco-22-90.
- Miller R, Song A, Ali A, Niazi M, Bar-Ad V, Martinez N, Glass J, Alnahhas I, Andrews D, Judy K, Evans J, Farrell C, Werner-Wasik M, Chervoneva I, Ly M, Palmer J, Liu H, Shi W. Scalp-Sparing Radiation With Concurrent Temozolomide and Tumor Treating Fields (SPARE) for Patients With Newly Diagnosed Glioblastoma. Front Oncol. 2022 Apr 29;12:896246. doi: 10.3389/fonc.2022.896246. eCollection 2022.
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Aktuální)
Dokončení studie (Aktuální)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
- TRIDENT EF-32
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .